TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32650731
Drug: CAIDE85+ study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAIDE85+ study intervention including cognitive evaluations (CERAD, Trail Making Test-A, Letter-Digit Substitution Test, Clinical Dementia Rating, Activities of Daily Living) and assessments of physical health status, psychosocial wellbeing, and blood biomarkers relevant for dementia and ageing.
Study: 32650734
Drug: General medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: General medicine with acute bacterial infections
Study: 32651887
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release naltrexone treatment starting in the week prior to release from prison
Study: 32651996
Drug: Antithrombotic therapies
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapies prescribed after percutaneous coronary intervention
Study: 32652442
Drug: Pamiparib (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib (3 mg/kg)
Study: 32652442
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pamiparib with Temozolomide (TMZ)
Study: 32653053
Drug: Margetuximab 15
Normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Margetuximab 15 mg/kg plus pembrolizumab 200 mg intravenously every 3 weeks (recommended phase 2 dose)
Study: 32653053
Drug: Margetuximab 10
Normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Margetuximab 10 mg/kg plus pembrolizumab 200 mg intravenously every 3 weeks (dose-escalation phase)
Study: 32653622
Drug: Ixazomib (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib (4 mg, oral, weekly for 4 doses from days +60 to +90)
Study: 32655854
Drug: Low-dose scopolamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose scopolamine
Study: 32655940
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 1.25 mg (0.05 ml) bevacizumab followed by phacoemulsification, pars plana vitrectomy (PPV) including panretinal photocoagulation (PRP), and trabeculectomy with mitomycin C (MMC)
Study: 32656160
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of candesartan (16 mg) and amlodipine (10 mg)
Study: 32656160
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of individual formulations of candesartan (16 mg) and amlodipine (10 mg)
Study: 32657505
Drug: Sebelipase alfa
Normalized name: Sebelipase alfa
DrugBank: Sebelipase alfa (DB11563)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sebelipase alfa (1.0 or 3.0 mg/kg every other week) for up to 5 years
Study: 32658816
Drug: Manic phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manic phase (before treatment)
Study: 32658816
Drug: Euthymic phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euthymic phase (post treatment)
Study: 32659786
Drug: Glucocorticoids administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucocorticoids administration
Study: 32660470
Drug: Bronchodilator response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bronchodilator response (BDR) in FEV1
Study: 32660470
Drug: Limit of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limit of 400 mL in BDR in FEV1
Study: 32660613
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment for one year
Study: 32661003
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg raltegravir twice daily
Study: 32661186
Drug: Buparlisib in
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib in combination with temozolomide (stage I)
Study: 32661186
Drug: Buparlisib in
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib in combination with temozolomide and radiotherapy (stage II)
Study: 32661186
Drug: Buparlisib in
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib in combination with temozolomide and radiotherapy
Study: 32661752
Drug: 670 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 670 nm photobiomodulation (PBM) delivered via a retinal laser, 12 sessions over 5 weeks, 90 seconds per treatment at settings of 25, 100 or 200 mW/cm²
Study: 32662547
Drug: Actionable pharmacogenomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actionable pharmacogenomic diplotypes/phenotypes for medications including tacrolimus, azathioprine, clopidogrel, warfarin, simvastatin, voriconazole, antidepressants, and proton-pump inhibitors.
Study: 32662758
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low BMD (<80 mg/cm³)
Study: 32663093
Drug: Pediatric weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric weight management interventions; details on dosage and duration not available.
Study: 32664901
Drug: Long-term opioid
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term opioid therapy (LTOT)
Study: 32664901
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-opioid analgesics)
Study: 32665297
Drug: Neoadjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pembrolizumab (200 mg)
Study: 32665314
Drug: High-normal eGFR
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-normal eGFR (≥103.9 mL/min/1.73 m²)
Study: 32665314
Drug: Deciles 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deciles 1, 9, and 10 (eGFR <50.9, 50.9-62.7, and ≥103.9 mL/min/1.73 m²)
Study: 32665855
Drug: Preoperative fluoropyrimidine
Normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative fluoropyrimidine with radiotherapy (standard treatment)
Study: 32666050
Drug: Vinblastine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine and nilotinib combination (vinblastine once weekly, nilotinib orally BID for 12 cycles of 28 days)
Study: 32666871
Drug: SELUTION Sustained-Limus-Release
Normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SELUTION Sustained-Limus-Release Drug-Eluting Balloon
Study: 32667729
Drug: Renin-angiotensin system
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system (RAS) drugs
Study: 32667729
Drug: RAS blocker
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RAS blocker monotherapy
Study: 32667729
Drug: RAS blocker/diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS blocker/diuretic combo
Study: 32669223
Drug: Optimal pharmacological
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal pharmacological treatment (OPT) including lipid lowering drugs
Study: 32669223
Drug: Overall prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall prescription prevalence of OPT
Study: 32669223
Drug: Time trends
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time trends in prescription prevalence of OPT
Study: 32669376
Drug: Encorafenib (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib (450 mg) plus Binimetinib (45 mg)
Study: 32669548
Drug: HER2 CAR
Normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HER2 CAR T cells after lymphodepleting chemotherapy, followed by four more CAR T-cell infusions without lymphodepletion.
Study: 32669548
Drug: Additional CAR
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional CAR T-cell infusions with pembrolizumab.
Study: 32669548
Drug: 20 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20 months off T-cell infusions.
Study: 32670103
Drug: Standardized antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized antidepressant therapy
Study: 32670418
Drug: 15-mg crocin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mg crocin, twice daily, for 12 weeks
Study: 32670424
Drug: UGN-101 (mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-101 (mitomycin gel)
Study: 32670599
Drug: 16-week heavy
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-week heavy shoulder strengthening exercise programme (3 times weekly) targeting scapular and rotator cuff muscles
Study: 32670812
Drug: Ketogenic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic diet supplemented with 10 g essential amino acids
Study: 32673071
Drug: Chemokine Receptor
Normalized name: Chemokine receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemokine Receptor 2-targeted Molecular Imaging
Study: 32673265
Drug: Del Nido
Normalized name: Del Nido Cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Del Nido cardioplegia solution (DNS)
Study: 32673265
Drug: Cardi-Braun blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardi-Braun blood cardioplegia solution
Study: 32673270
Drug: Peer-led physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-led physical activity intervention (3-month duration, 6 biweekly video chat sessions, Fitbit Charge 3, weekly feedback)
Study: 32673385
Drug: Rituximab/chemotherapy (R-Chemo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab/chemotherapy (R-Chemo)
Study: 32673446
Drug: Fedratinib 500
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fedratinib 500 mg daily for 14 days
Study: 32674634
Drug: Evolocumab, 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab, 480 mg every 4 weeks for 6 weeks
Study: 32676702
Drug: Patients treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with metformin and/or statins
Study: 32676980
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living measured by IBM-FRS
Study: 32677106
Drug: (+)-Epicatechin (EPI)
Normalized name: epicatechin
DrugBank: Epicatechin (DB12039)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-Epicatechin (EPI) at 75 mg/d for 24 weeks, escalating to 150 mg/d at 12 weeks if no improvement
Study: 32677968
Drug: Hepatitis-B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis-B vaccine with five different adjuvant formulations
Study: 32678436
Drug: 6-week blueberry-enriched
Normalized name: BLUEBERRY
DrugBank: Blueberry (DB10629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week blueberry-enriched diet (38 g of freeze-dried blueberries daily)
Study: 32680480
Drug: Ambrisentan 5
Normalized name: ambrisentan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 5 mg once daily for 12 weeks, followed by 12-week dose titration (up to 10 mg)
Study: 32680541
Drug: Intraovarian injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAOVARIAN LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraovarian injection of autologous bone marrow-derived mesenchymal stem cells
Study: 32681140
Drug: Low anterior
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low anterior resection for rectal cancer
Study: 32681682
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg once daily (EXP3B subgroup)
Study: 32681700
Drug: sST2 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sST2 levels ≥35 ng/mL among survivors
Study: 32682670
Drug: Ataluren (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ataluren (a read-through agent for premature nonsense codons)
Study: 32682875
Drug: Sleep medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep medications (including benzodiazepines)
Study: 32683528
Drug: Microgravity exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgravity exposure (μg)
Study: 32683644
Drug: IV tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tramadol 25 mg
Study: 32687189
Drug: Saliva Iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saliva Iodine Concentration (SIC) <105 μg/L
Study: 32687189
Drug: Saliva Iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saliva Iodine Concentration (SIC) >273 μg/L
Study: 32687629
Drug: Pharmacological interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacological interventions (weight loss medications, medication switching)
Study: 32687977
Drug: Rectal location
Normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal location
Study: 32687977
Drug: Logistic regression
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Logistic regression model based on lesion size and rectal location
Study: 32687977
Drug: NNT for
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNT for rectal SMIC of 4 cm or more
Study: 32690535
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients who refused ASV or stopped treatment early)
Study: 32690731
Drug: Serological HPA-1a
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serological HPA-1a typing and luminex-based multiplex assay for detection of anti-HPA-1a antibodies.
Study: 32690735
Drug: Classic permissive
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classic permissive strategy of antibiotic prophylaxis and treatment
Study: 32690797
Drug: bimagrumab 10
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bimagrumab 10 mg/kg IV every 4 weeks up to 2 years (104 weeks)
Study: 32691242
Drug: Idarucizumab (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (2.5 + 2.5 g, intravenous) administered 2 hours after the last administration of dabigatran etexilate (220 mg b.i.d., oral)
Study: 32691242
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (220 mg b.i.d., oral) alone
Study: 32692367
Drug: 3.5 g
Normalized name: Calcium 760 MG/3.5 GM Oral Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g GOS
Study: 32692367
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g GOS
Study: 35015879
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g GOS
Study: 32692367
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g GOS with 93 mg AA
Study: 32692450
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg daily for days 1-21 of 28-day cycles)
Study: 34496014
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg IV every 3 weeks
Study: 32695577
Drug: Korean medicine
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean medicine treatments for LBP
Study: 32695923
Drug: Educational programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational programme for blood management (non-drug intervention) in group A
Study: 32695923
Drug: Systematic correction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic correction of perioperative iron, vitamin deficiencies, and anaemia (drug intervention) in group B
Study: 32695954
Drug: Home-based rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based rehabilitation program (twice a week for 3 months)
Study: 32696319
Drug: TTC-352 (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTC-352 (180 mg twice a day)
Study: 32696441
Drug: Darunavir 600
Normalized name: darunavir 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir 600 mg q24h
Study: 32696441
Drug: Darunavir 400
Normalized name: darunavir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir 400 mg q24h
Study: 32696441
Drug: Darunavir 800
Normalized name: darunavir 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir 800 mg q24h for 5 days followed by 2 days of treatment interruption
Study: 32696441
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment guidelines (darunavir 800 mg q24h or 600 mg q12h)
Study: 32696663
Drug: Antithrombotic management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic management focusing on stroke/systemic embolism prevention, uptake of new oral anticoagulants
Study: 32696697
Drug: Enriched marine
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched marine oil supplement (3 escalating doses, 5-day oral administration)
Study: 32698195
Drug: Zanubrutinib 160
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 160 mg orally twice daily (n = 50)
Study: 32698195
Drug: Zanubrutinib 320
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 320 mg orally once daily (n = 23)
Study: 32698532
Drug: Papaya Mosaic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaya Mosaic Virus adjuvant (30 to 240 µg) combined with trivalent influenza vaccine
Study: 32698642
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of cefazolin
Study: 32698642
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of cefuroxime
Study: 34859113
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cefazolin
Study: 32698642
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of cefazolin (knee)
Study: 32698642
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of cefuroxime (knee)
Study: 32698642
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cefazolin (knee)
Study: 32699021
Drug: Vaginal brachytherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal brachytherapy or no adjuvant treatment
Study: 32699580
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant (FS) applied circumferentially after anastomosis (2.5 mL of porcine FS)
Study: 32699642
Drug: Executive Functioning
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Executive Functioning for Enhancing Community-based Treatment for ASD (EFFECT for ASD)
Study: 32699643
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) 1 g at the start and end of surgery
Study: 32699643
Drug: Oral rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rosuvastatin 40 mg before and 20 mg daily for 30 days after surgery
Study: 32699645
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral treatment for gambling
Study: 32699926
Drug: Breast-Conserving Therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-Conserving Therapy (BCT) with whole-breast radiation
Study: 32700065
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg AG-221 oral dose
Study: 32700765
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with hormone receptor (HR) positive metastases
Study: 32701541
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injections (ESI) for leg pain
Study: 34880117
Drug: Sacroiliac joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacroiliac joint (SIJ) injections
Study: 32702156
Drug: Peri-interventional dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-interventional dual antiplatelet therapy (DAPT)
Study: 32702156
Drug: Concurrent surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent surgery
Study: 32703167
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant rehabilitation
Study: 32704173
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily and Lenalidomide 25 mg daily
Study: 32704173
Drug: Everolimus and
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus and Lenalidomide combination
Study: 32709218
Drug: Early-stage ADPKD
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-stage ADPKD treatment options (specific treatment details not provided)
Study: 32709235
Drug: Pre- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and post-bronchodilator spirometry tests
Study: 32710011
Drug: Antibody-radionuclide conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibody-radionuclide conjugate targeting CD45